Literature DB >> 8096762

Pediatric osteosarcoma: treatment of the primary tumor with intraarterial cis-diamminedichloroplatinum-II (CDP)--advantages, disadvantages, and controversial issues.

N Jaffe.   

Abstract

Cumulative courses of intraarterial CDP are highly effective for treatment of the primary tumor in osteosarcoma. The response permitted limb-salvage procedures to be performed in a majority of patients. Responses induced in the primary tumor with multiagent chemotherapy, including reduced doses of CDP, were similar to those obtained with cumulative courses of intraarterial CDP. It is suggested that identical results may be attained with single-agent intravenous CDP by augmenting the dose intensity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8096762     DOI: 10.1007/978-1-4615-3518-8_11

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN: 0927-3042


  2 in total

1.  MicroRNA-21 regulates the sensitivity to cisplatin in a human osteosarcoma cell line.

Authors:  W Ziyan; L Yang
Journal:  Ir J Med Sci       Date:  2014-11-09       Impact factor: 1.568

2.  Targeting Notch1 signaling pathway positively affects the sensitivity of osteosarcoma to cisplatin by regulating the expression and/or activity of Caspase family.

Authors:  Lei Wang; Fangchun Jin; An Qin; Yongqiang Hao; Yufeng Dong; Shengfang Ge; Kerong Dai
Journal:  Mol Cancer       Date:  2014-06-03       Impact factor: 27.401

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.